Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Breast Neoplasms 3Neoplasm Metastasis 2Multiple Myeloma 2Sarcoma, Ewing 1Osteoporotic Fractures 1Osteoporosis 1Neoplasms, Plasma Cell 1Musculoskeletal Pain 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Renal Cell 1Arthralgia 1

Interventions

Dexamethasone 420Lenalidomide 265Cyclophosphamide 246Bortezomib 242Melphalan 192Calcium Dobesilate 166fludarabine phosphate 112daratumumab 103Peripheral Blood Stem Cell Transplantation 99carfilzomib 92Thalidomide 90Filgrastim 88Mycophenolic Acid 82fludarabine 81pomalidomide 80Whole-Body Irradiation 80Busulfan 74Tacrolimus 71Granulocyte Colony-Stimulating Factor 66Cyclosporine 58dexamethasone acetate 56ixazomib 55Antilymphocyte Serum 50dexamethasone 21-phosphate 49auricularum 44isatuximab 40Etoposide 39Radiotherapy 36Stem Cell Transplantation 34Methotrexate 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Multiple Myeloma × Diphosphonates × Clear all
NCT01215344 2018-05-15

First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade

Vanderbilt-Ingram Cancer Center

Phase 2 Completed
36 enrolled 8 charts
Plasma cell

Multiple Myeloma

NCT00222053 2010-04-02

IFM 99-02 Thalidomide in Myeloma

University Hospital, Toulouse

Phase 3 Completed
800 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡